Drug Profile
Research programme: cancer and heart failure therapies - Zensun (Shanghai) Sci & Tech
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Zensun (Shanghai) Sci & Tech
- Class Antineoplastics; Heart failure therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Heart failure
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in China
- 28 Aug 2020 No recent reports of development identified for preclinical development in Heart-failure in China
- 18 Jul 2016 Preclinical trials in Cancer in China (unspecified route)